MYC and neoplasm: For example, patients with NF1 A26465S (0.6%) at baseline experienced an 11% tumor reduction after 4 months of sotorasib treatment, and patients with SCLC with treatment-emerging NF1 N1004Ifs∗8 (0.3%) progressed with a 58% increase in tumor size, accompanied by MYC amplification (3.5-fold).31